Presently, the approved therapeutic agents used in the temporary control of clinical symptoms of PD include levodopa/carbidopa, dopamine agonists, monoamine oxidase-B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, anticholinergics, and amantadine. This evidence concerns the gene COMT and Parkinson disease.